Azione 503 LANSEN PHARMACEUTICAL HOLDINGS LIMITED
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati
Strumento inattivo

Altre lingue Lansen Pharmaceutical Holdings Limited

Azioni

503

KYG5380M1033

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Lansen Pharmaceutical to Delist from HKEX on Dec. 19
Cayman Islands Court Approves Takeover, Privatization of Lansen Pharma
Cathay International Holdings Limited completed the acquisition of additional 31.78% stake in Lansen Pharmaceutical Holdings Limited.
Cathay International Pharma to Privatize Lansen Pharmaceutical in HK$239 Million Deal
Lansen Pharmaceutical's H1 Profit Slides 17%
Lansen Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Lansen Pharmaceutical Holdings Limited commences an Equity Buyback Plan for 42,243,243 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2023.
Lansen Pharmaceutical Holdings Limited's Equity Buyback announced on June 24, 2022, has expired.
Tranche Update on Lansen Pharmaceutical Holdings Limited's Equity Buyback Plan announced on June 24, 2022.
Lansen Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022
Lansen Pharmaceutical Holdings Limited Declares Interim Dividend
Lansen Pharmaceutical Expects 2022 Profit Soaring 798%; Shares Surge 22%
Lansen Pharmaceutical Holdings Limited Provides Earnings Guidance for the Twelve Months Ended 31 December 2022
Lansen Pharmaceutical Holdings Limited Appoints Zhu Xun as Independent Non-Executive Director and Member of the Remuneration Committee
Tranche Update on Lansen Pharmaceutical Holdings Limited's Equity Buyback Plan announced on June 24, 2022.
Lansen Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2022
Lansen Pharmaceutical Holdings Limited commences an Equity Buyback Plan for 42,683,400 shares, representing 10% of its issued share capital, under the authorization approved on June 23, 2022.
Lansen Pharmaceutical Holdings Limited Approves to Elect Chan Ching Har, Eliza as an Independent Non-Executive Director
Lansen Pharmaceutical Holdings Limited's Equity Buyback announced on June 2, 2021, has expired.
Lansen Pharma Sees Better Financial Performance in H1
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione 503
  4. Notizie Lansen Pharmaceutical Holdings Limited
  5. Altre lingue